Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ATAI | Convertible Notes | Other | -148K | -100% | 0 | Apr 15, 2024 | Common Shares | 2.37M | By Apeiron Investment Group Ltd. | F1, F2, F3, F4 | |||
transaction | ATAI | Convertible Notes | Other | +148K | 148K | Apr 15, 2024 | Common Shares | 2.37M | By Apeiron Investment Group Ltd. | F1, F2, F3, F4 |
Id | Content |
---|---|
F1 | The conversion price for the Convertible Notes is EUR 17.00 per note. |
F2 | Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics. |
F3 | Each Convertible Note bears a notional principal amount of EUR 1.00. |
F4 | The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities. |